|
(Health-NewsWire.Net, October 19, 2020 ) The overall peptide synthesis market was valued at USD 292.4 million in 2017 and is projected to reach USD 426.4 million by 2023, at a CAGR of 6.5% during the forecast period. Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers.
Drivers:
# Increasing use of peptides in pharmaceutical drugs
# Increase in research activities and availability of funding for R&D
# Development of advanced peptide synthesizers
Restraints:
# Lack of a unified set of regulations for therapeutic peptides
Opportunities:
# Emerging markets in the Asia Pacific region
Challenges:
# Issues associated with the route of administration of peptide drugs
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365
Industry Segmentation:
By technology, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023
Based on technology, the peptide synthesis market has been segmented into solid-phase synthesis, liquid-phase synthesis and recombinant technology. In 2017, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are driving the growth of the solid-phase synthesis segment.
Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017
Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.
Geographical Growth:
The peptide synthesis market in APAC is expected to grow at the highest CAGR during the forecast period. With significant growth in the research industry in the past few years, China and India have emerged as high-growth markets peptide synthesis. The research industry in this region has grown significantly over the years; manufacturers are now focusing on providing well-established technologies to ensure sustainable and strong revenue growth from this region.
Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry, as reflected in the increase in research being undertaken and government funds provided for these drugs. Thus, the increasing demand for novel antibody and protein-based drugs along with growing investments by the public and private sectors in life science research are expected to drive the APAC market in the coming years.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365
The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. The global peptide synthesis market is a fragmented market. GenScript Biotech Corporation (China), Merck KGAA (Germany), AAPPTec (US), Bachem (Switzerland), and Biotage (Sweden) dominated the global peptide synthesis market in 2017.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
